Exemestane in Advanced and Recurrent Endometrial Carcinoma

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma

Hypothesis: Treatment With Exemestane can give a response rate of at least 30%

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nordic Society for Gynaecologic Oncology; Nordic Society of Gynaecological Oncology - Clinical Trials Unit
• Treatments: Exemestane

Criteria

Inclusion Criteria:

• Advanced or recurrent endometrial cancer not considered for treatment modalities apart from hormonal treatment

• Endometrioid histology

• Age above 18 years

• Post menopausal status

• Performance status 0-2

• Informed consent

Exclusion Criteria:

• Congestive heart disease grade III.IV

• History of thromboembolic signs

• Other primary hormonal therapy

• Patients With symptomatic brain metastasis

• Severe hepatic or renal impairment

• Pregnancy, lactation or child bearing potential without adequate contraception